Abstract
Radiation nephropathy and other normal tissue radiation injuries can be successfully mitigated, and also treated, by antagonists of the renin-angiotensin system (RAS). This implies a mechanistic role for that system in radiation nephropathy, yet no evidence exists to date of activation of the RAS by irradiation. RAS antagonists, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are the standard of care in the treatment of subjects with other chronic progressive kidney diseases, in which they exert benefit by reducing both glomerular and tubulo-interstitial injury. These drugs are likely to act in a similar way to mitigate radiation nephropathy.
Keywords: Radiation injuries, radiation nephropathy, renin-angiotensin system, angiotensins, captopril, mesangiolysis, Radiation, nephropathy, angiotensin, (TBI), (BMT), Mitigation, (ACE), (BUN), (DMFs), losartan, (HSCT), RAS, (NO), (AcSDKP), bradykinin, (AVE0991), DNA, NADPH oxidase, glomerular
Current Drug Targets
Title: Mitigation of Radiation Injuries via Suppression of the Renin-Angiotensin System: Emphasis on Radiation Nephropathy
Volume: 11 Issue: 11
Author(s): E. P. Cohen, B. L. Fish and J. E. Moulder
Affiliation:
Keywords: Radiation injuries, radiation nephropathy, renin-angiotensin system, angiotensins, captopril, mesangiolysis, Radiation, nephropathy, angiotensin, (TBI), (BMT), Mitigation, (ACE), (BUN), (DMFs), losartan, (HSCT), RAS, (NO), (AcSDKP), bradykinin, (AVE0991), DNA, NADPH oxidase, glomerular
Abstract: Radiation nephropathy and other normal tissue radiation injuries can be successfully mitigated, and also treated, by antagonists of the renin-angiotensin system (RAS). This implies a mechanistic role for that system in radiation nephropathy, yet no evidence exists to date of activation of the RAS by irradiation. RAS antagonists, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are the standard of care in the treatment of subjects with other chronic progressive kidney diseases, in which they exert benefit by reducing both glomerular and tubulo-interstitial injury. These drugs are likely to act in a similar way to mitigate radiation nephropathy.
Export Options
About this article
Cite this article as:
P. Cohen E., L. Fish B. and E. Moulder J., Mitigation of Radiation Injuries via Suppression of the Renin-Angiotensin System: Emphasis on Radiation Nephropathy, Current Drug Targets 2010; 11 (11) . https://dx.doi.org/10.2174/1389450111009011423
DOI https://dx.doi.org/10.2174/1389450111009011423 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obesity, Diabetes and Cardiovascular Diseases in India: Public Health Challenges
Current Diabetes Reviews Necrotizing Enterocolitis: Clinical Features, Histopathological Characteristics, and Genetic Associations
Current Pediatric Reviews The Pulmonary Renin-Angiotensin System
Current Pharmaceutical Design Sympathetic Activation in Hypertension and in Hypertension-Related Metabolic Disease
Current Hypertension Reviews Editorial [Hot Topic: Phosphodiesterase 5 Inhibitors: Pharmacology and Therapeutic Perspectives (Executive Editor: Giuseppe Barbaro)]
Current Pharmaceutical Design Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine From the Stretcher to the Pharmacys Shelf: Drug Leads from Medically Important Brazilian Venomous Arachnid Species
Inflammation & Allergy - Drug Targets (Discontinued) Modulation of Collagen Turnover in Cardiovascular Disease
Current Pharmaceutical Design Chemometric Assisted Simultaneous Analysis of Verapamil Hydrochloride, Gliclazide and Simvastatin in Bulk Drug and Fixed Dose Combinatinos (polypill) - A Futuristic Approach
Current Analytical Chemistry Preparation and in vitro/in vivo Evaluation of Lacidipine by Adsorption onto Fumed Silica Using Supercritical Carbon Dioxide
Current Drug Delivery Editorial (Thematic Issue: Cardiovascular Prevention: Can We Do Any Better?)
Current Pharmaceutical Design The Neuropeptide Galanin Benefits Insulin Sensitivity in Subjects with Type 2 Diabetes
Current Protein & Peptide Science Connexins, Diabetes and the Metabolic Syndrome
Current Protein & Peptide Science GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer’s Disease Patients
Current Alzheimer Research Treatment of Carotid Stenosis
Current Vascular Pharmacology Hydrolyzates of Silkworm Pupae (Bombyx Mori) Protein is a New Source of Angiotensin I-Converting Enzyme Inhibitory Peptides(ACEIP)
Current Pharmaceutical Biotechnology Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO)
Current Vascular Pharmacology The Emerging Role of Bradykinin in the Pathogenesis of Osteoarthritis and its Possible Clinical Implications
Current Rheumatology Reviews FXR, A Therapeutic Target for Bile Acid and Lipid Disorders
Mini-Reviews in Medicinal Chemistry Mapping of the Active Site of Proteases in the 1960s and Rational Design of Inhibitors/Drugs in the 1990s
Current Protein & Peptide Science